# Olema Pharmaceuticals

Source: https://onco.cc/companies/olema-pharmaceuticals/  
OnCo record `olema-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Olema Pharmaceuticals is a United States-based biotechnology company running 2 late-stage cancer trials in HR-positive / HER2-negative breast cancer.

## Summary

Olema Pharmaceuticals, based in San Francisco, the United States, is a biotechnology company listed as NASDAQ: OLMA. Olema Oncology is a clinical-stage biopharmaceutical company focused on discovering, developing and commercialising targeted therapies for breast cancer, drawing on expertise in endocrine-driven cancers and nuclear receptors. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3) in HR-positive / HER2-negative breast cancer. The largest, NCT07085767 (Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer), plans to enrol 1000 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Olema Pharmaceuticals, Inc.
- Tags: ctgov-sponsor
- HQ: San Francisco
- Type: biotech
- Website: https://www.olema.com
- Ticker: NASDAQ: OLMA

## Sources

- Official website: https://www.olema.com
- ClinicalTrials.gov: trials led by Olema Pharmaceuticals: https://clinicaltrials.gov/search?lead=Olema%20Pharmaceuticals%2C%20Inc.
- Pipeline page: https://www.olema.com/pipeline

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- drugs: [Ribociclib](https://onco.cc/drugs/ribociclib/)
- trials: [OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer](https://onco.cc/trials/nct06016738/), [Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer](https://onco.cc/trials/nct07085767/)

---
JSON: https://onco.cc/api/v1/entities/olema-pharmaceuticals.json